EFFICIENCY AND SAFETY OF USING PIDOTIMOD IN VACCINATED RISK GROUP CHILDREN
https://doi.org/10.15690/pf.v10i1.591
Abstract
The article is dedicated to the use of immunomodulators in children, conditions, at which the prescription of this group of drugs is reasonable, action mechanism and also efficacy are given. In particular, the authors give their observation results for a group of HPV-infected children vaccinated by live vaccines (rubella and divalent measles-parotitis vaccine) together with pidotimod usage. No undesirable phenomena were registered in the postvaccinal period. Dynamics of immunological indicators did not change significantly. Seroconversion level of measles antibodies totaled 100% by the 30th observation day.
About the Authors
A. A. Ruleva
Research institute of children’s infections at the Federal Medical-Biological Agency, Saint Petersburg, Russian Federation
Junior research scientist at the infectious diseases’ prevention department, FSBI “Research institute of children’s infections at the FMBA of Russia”.
S. M. Kharit
Research institute of children’s infections at the Federal Medical-Biological Agency, Saint Petersburg, Russian Federation
E. P. Nacharova
Research institute of children’s infections at the Federal Medical-Biological Agency, Saint Petersburg, Russian Federation
I. V. Fridman
Research institute of children’s infections at the Federal Medical-Biological Agency, Saint Petersburg, Russian Federation
References
1. Khaitov R.M., Pinegin B.V. Immunomodulators: classification, pharmacological action, clinical application. Farmateka = Farmateka. 2004; 7: 10–15.
2. Khaitov R.M., Pinegin B.V. Osnovnye printsipy immunomoduliruyushchei terapii. V kn.: Ribosomal'naya immunokorrektsiya v praktike pediatra [Basic Principles of Immunomodulating Therapies. In the book: Ribosomal. Immunotherapy in Pediatric Practice]. Moscow, 2006. pp. 7–15.
3. Chernova N.D., Kuz'menko L.D., Smirnova T.N., Samsonova E.I. Immunotherapy in RRI children on an outpatient basis. Detskie infektsii = Child infections. 2004; 2 (7): 46–49.
4. Namazova L.S., Botvin'eva V.V., Voznesenskaya N.I. Contemporary capabilities of immunotherapy in RRI children with allergies. Pediatricheskaya farmakologiya = Pediatric pharmacology. 2007; 1 (4): 27–32.
5. Guidelines on use of International Noneproprietary Names (INNs) for Pharmaceutical Substances. WHO/Pharm S/Nom 1570. WHO. Geneva. 1997.
6. . Namazova-Baranova L.S., Vishneva E.A. Modern view on immunomodulating therapy. Voprosy sovremennoi pediatrii = Current pediatrics. 2012; 11 (1): 143–146.
7. Burgio G. R., Marseglia G. L., Severi F., Masarone M., Ottolenghi A., Pagliano L., Serra V., Nespoli L. Immunoactivation by pidotimod in children with recurrent respiratory infections. Arzneimittelforschung. 1994; 44: 1525–1529.
8. Capsoni F., Minonzio F., Ongari A. M., Girardello R., Di Bello M., Zanussi C. In vitro and ex vivo enhancement of neutrophil functions by PGT/1A, a new immunostimulating peptide. J. Chemother. 1991; 3: 147–149.
9. Pugliese A., Uslenghi C., Torre D., D’Alonzo L., Corgnati F., Girar del lo R. Evaluation of the effect of pidotimod on the in vitro production of interferons. Int. J. Immunotherapy. 1995; 11: 71–76.
10. Lyanko N.M. Kliniko-immunologicheskaya kharakteristika AKDS i korevogo vaktsinal'nogo protsessa u detei, rozhdennykh ot VICh-infitsirovannykh materei. Avtoref. dis. … kand. med. nauk [Clinical and Immunological Features of DTP and Measles Vaccination Process in Children Born to HIV-infected Mothers. Author’s abstract]. St. Petersburg, 2006.
11.
Review
For citations:
Ruleva A.A., Kharit S.M., Nacharova E.P., Fridman I.V. EFFICIENCY AND SAFETY OF USING PIDOTIMOD IN VACCINATED RISK GROUP CHILDREN. Pediatric pharmacology. 2013;10(1):70-73. https://doi.org/10.15690/pf.v10i1.591
Views:
714
Email this article 